Test and Prevent: Evaluation of a Pilot Program Linking Clients With Negative HIV Test Results to Pre-exposure Prophylaxis in Zimbabwe.
Journal
Global health, science and practice
ISSN: 2169-575X
Titre abrégé: Glob Health Sci Pract
Pays: United States
ID NLM: 101624414
Informations de publication
Date de publication:
31 03 2021
31 03 2021
Historique:
received:
27
07
2020
accepted:
22
12
2020
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
26
10
2021
Statut:
epublish
Résumé
As HIV testing increases worldwide, programs are reaching individuals without HIV infection who are at risk of exposure and may be candidates for oral pre-exposure prophylaxis (PrEP). Although linkage of individuals with HIV infection to treatment is a global priority (referred to as "test and treat"), less attention is given to individuals with negative HIV test results. We developed the "Test and Prevent" pilot program to intentionally link at-risk clients with negative HIV test results to PrEP services. The intervention included risk assessment of all clients with a negative result from HIV testing (with national risk assessment tool), accompanied referral, fast-tracking, and targeting follow-up. The intervention was conducted in Bulawayo, Zimbabwe, at 6 public sector sites from October 2019 to February 2020. We collected routine monitoring data from all study sites and tracked referral completion and PrEP initiation among clients who enrolled. We conducted in-depth interviews with providers (n=12), facility managers (n=5), and female clients (n=17) to explore acceptability. Among clients referred for PrEP (n=206), 98% completed their referrals and started PrEP. However, only 3% of clients who received a negative test result during the study period were referred. Low referrals stemmed from lack of screening (39% of clients with negative HIV test results were not screened) and lack of eligibility among clients who were screened (only 6% of those screened qualified as candidates for PrEP per the national screening tool). Qualitative results indicate that some providers purposefully did not complete screening with clients they felt were not at risk and that workload could have contributed to low screening uptake.Qualitative interviews showed that Test and Prevent was acceptable among both providers and clients. Clients were happy to learn about PrEP following HIV testing, and the additional support of accompanied referrals and fast-tracking encouraged them to access PrEP and made them feel valued. Providers were burdened by workload constraints but felt that Test and Prevent was important and should be scaled to other sites. Intentionally linking clients with negative results to PrEP immediately following HIV testing was found to be acceptable from both provider and client perspectives, yet screening procedures need closer examination and reinforcement for the program to realize a larger impact.
Sections du résumé
BACKGROUND
As HIV testing increases worldwide, programs are reaching individuals without HIV infection who are at risk of exposure and may be candidates for oral pre-exposure prophylaxis (PrEP). Although linkage of individuals with HIV infection to treatment is a global priority (referred to as "test and treat"), less attention is given to individuals with negative HIV test results. We developed the "Test and Prevent" pilot program to intentionally link at-risk clients with negative HIV test results to PrEP services. The intervention included risk assessment of all clients with a negative result from HIV testing (with national risk assessment tool), accompanied referral, fast-tracking, and targeting follow-up.
METHODS
The intervention was conducted in Bulawayo, Zimbabwe, at 6 public sector sites from October 2019 to February 2020. We collected routine monitoring data from all study sites and tracked referral completion and PrEP initiation among clients who enrolled. We conducted in-depth interviews with providers (n=12), facility managers (n=5), and female clients (n=17) to explore acceptability.
RESULTS
Among clients referred for PrEP (n=206), 98% completed their referrals and started PrEP. However, only 3% of clients who received a negative test result during the study period were referred. Low referrals stemmed from lack of screening (39% of clients with negative HIV test results were not screened) and lack of eligibility among clients who were screened (only 6% of those screened qualified as candidates for PrEP per the national screening tool). Qualitative results indicate that some providers purposefully did not complete screening with clients they felt were not at risk and that workload could have contributed to low screening uptake.Qualitative interviews showed that Test and Prevent was acceptable among both providers and clients. Clients were happy to learn about PrEP following HIV testing, and the additional support of accompanied referrals and fast-tracking encouraged them to access PrEP and made them feel valued. Providers were burdened by workload constraints but felt that Test and Prevent was important and should be scaled to other sites.
CONCLUSION
Intentionally linking clients with negative results to PrEP immediately following HIV testing was found to be acceptable from both provider and client perspectives, yet screening procedures need closer examination and reinforcement for the program to realize a larger impact.
Identifiants
pubmed: 33795361
pii: GHSP-D-20-00444
doi: 10.9745/GHSP-D-20-00444
pmc: PMC8087428
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
40-54Subventions
Organisme : PEPFAR
Pays : United States
Informations de copyright
© Stankevitz et al.
Références
AIDS Care. 2009 Feb;21(2):185-8
pubmed: 19229687
J AIDS Clin Res. 2017 Sep;8(9):
pubmed: 29201531
J Int AIDS Soc. 2016 Dec 19;19(1):21348
pubmed: 27989271
Lancet HIV. 2020 Dec;7(12):e825-e834
pubmed: 32622370
AIDS Behav. 2018 Mar;22(3):691-700
pubmed: 28752353
Clin Infect Dis. 2017 Mar 15;64(6):751-758
pubmed: 28034882
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):19979
pubmed: 26198344
J Int AIDS Soc. 2019 Apr;22(4):e25276
pubmed: 31037845
Lancet HIV. 2020 Apr;7(4):e249-e261
pubmed: 32087152
Am J Public Health. 1993 Apr;83(4):529-33
pubmed: 8460729
J Int AIDS Soc. 2009 Nov 11;12:31
pubmed: 19906291
J Adolesc Health. 2018 Apr;62(4):424-433
pubmed: 29224988
AIDS. 2011 Mar 27;25(6):825-34
pubmed: 21252632
J Natl Med Assoc. 2006 Dec;98(12):1924-9
pubmed: 17225835
Curr HIV/AIDS Rep. 2014 Dec;11(4):376-92
pubmed: 25323298
AIDS. 2000 Mar 31;14(5):547-52
pubmed: 10780717
J Gen Intern Med. 2011 Aug;26(8):887-93
pubmed: 21523496
PLoS One. 2018 Aug 10;13(8):e0197904
pubmed: 30096139
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):333-43
pubmed: 26918545
PLoS One. 2016 Apr 14;11(4):e0153612
pubmed: 27077745
J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e113-5
pubmed: 22033235
PLoS One. 2019 Jun 21;14(6):e0218556
pubmed: 31226165
Health Policy Plan. 2017 Jun 1;32(5):613-624
pubmed: 28064212
PLoS Med. 2017 Nov 14;14(11):e1002433
pubmed: 29136001
AIDS Behav. 2016 May;20(5):951-66
pubmed: 26404014
AIDS. 2012 Oct 23;26(16):2059-67
pubmed: 22781227
BMC Health Serv Res. 2014 May 21;14:231
pubmed: 24886646
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):339-47
pubmed: 23187945
PLoS One. 2019 Jan 22;14(1):e0210826
pubmed: 30668598